BMC Infectious Diseases · 2016 · 16 citations · 30 references
Public HealthInfectious Disease ControlInfectious DiseasesAntimicrobial ResistanceAntimicrobial Resistance EpidemiologyTuberculosis ControlAntibiotic ResistanceDrug ResistanceMultidrug ResistancePulmonary TuberculosisResistance EpidemiologyTuberculosis EpidemiologyDrug Resistance Pattern AnalysisDrug Resistance TestingDrug-resistant PathogensFluoroquinolone Resistance MechanismsMultidrug-resistant OrganismsMycobacterium Tuberculosis InfectionPan-drug ResistanceTuberculosis Drug Resistance
BACKGROUND: The spread of multidrug-resistant tuberculosis (MDR-TB) Mycobacterium tuberculosis (M. tuberculosis) strains has been a big challenge to the TB control and prevention in China. Knowledge about patterns of drug resistance in TB high-burden areas of China is crucial to develop appropriate control strategies. We conducted a comprehensive investigation of the resistance pattern of M. tuberculosis in Heilongjiang Province. METHODS: 1427 M. tuberculosis clinical strains were isolated from pulmonary TB patients hospitalized between 2007 and 2012. The susceptibility of the isolates to the first-line anti-TB drugs and the resistance of MDR M. tuberculosis to fluoroquinolones were examined. We also performed a statistical analysis to identify the correlated risk factors for high burden of MDR-TB. RESULTS: The global resistance rates of 2007-2012 to the first-line drugs and MDR were 57.0 and 22.8 %, respectively. Notably, the primary MDR-TB and pan-resistance rates were as high as 13.6 and 5.0 %, respectively. Of MDR M. tuberculosis isolates (2009), approximately 13 % were not susceptible to any of the fluoroquinolones tested. Being age of 35 to 54, high re-treatment proportion, the presence of cavity lesion, and high proportion of shorter hospitalization are correlated with the development of MDR-TB. CONCLUSIONS: The high prevalence of drug resistant, MDR-TB, and fluoroquinolone-resistant MDR-TB is a big concern for TB control. More importantly, in order to control the development of MDR-TB effectively, we need to pay more attention to the primary resistance. Targeting reducing the prevalence of the risk factors may lead to better TB control in China.
30
Dick van Soolingen, Peter W. M. Hermans, P E de Haas et al. · Journal of Clinical Microbiology · 1991 · 1K citations · Full text
National Survey of Drug-Resistant Tuberculosis in China
Yanlin Zhao, Shaofa Xu, Lixia Wang et al. · New England Journal of Medicine · 2012 · 645 citations · Full text
Richard C. Huard, Luiz Claudio de Oliveira Lazzarini, W. Ray Butler et al. · Journal of Clinical Microbiology · 2003 · 284 citations · Full text
Tracy Dalton, Peter Cegielski, Somsak Akksilp et al. · The Lancet · 2012 · 227 citations · Full text
Jann‐Yuan Wang, Li‐Na Lee, Hsin‐Chih Lai et al. · Journal of Antimicrobial Chemotherapy · 2007 · 136 citations · Full text